Ken, your math for the November snapshot is completely logical based on what was public at the time.
However, it's important to look at the actual mechanics of how conferences like the AACR handle these data cutoffs, as well as the speed this trial progressed once the safety hurdles were cleared. If you look at the physics of trial execution, there is in fact a high probability we see the 700mg data, and a patient population (N) much closer to 20 or more.
The data will likely be much more mature than just six or seven patients on 350mg:
1. The November Abstract is a "Placeholder," Not a Tombstone
The data submitted in a November abstract is not the exact same data that is presented on the April poster. That is not how the AACR operates.
Essentially, the November abstract is a "down payment" which secured spot. It proved to the peer-review committee that the biological trend is real.
In fact, the AACR explicitly encourages, and frankly expects, researchers to present the most updated, mature data available at the time the actual poster is printed. Even if the November abstract only referenced the first 5 to 7 patients on 350mg, Dr. Jay and the Creatv Bio team have been continuously feeding new patient data (including the 700mg cohort) into the final April poster.
2. The Late-Breaking & Clinical Trial Window
You noted that if this is a "Clinical Trials" abstract, they can add data as they go. You are 100% correct.
Furthermore, if the initial data was significant enough, the company had the option to utilize the Late-Breaking Abstract deadline, which typically locks in late January or early February. A February data-lock gives them an additional three to four months of clinical runway beyond that mid-November PR, all the way through late February cutoff.
3. The DSMB and the "700mg Floodgate"
You mentioned that the DSMB (Data Safety Monitoring Board) had to look at the 350mg data before authorizing the 700mg dose, which causes a delay.
In oncology, a safety run-in for a new dose usually requires monitoring the first 5 patients for Dose-Limiting Toxicities (DLTs) over a standard 21-to-28 day cycle.
As you know, Leronlimab is not a toxic chemotherapy; it has a remarkably benign safety profile established across thousands of previous patients. The DSMB review for the 350mg cohort was likely a rapid, rubber-stamp process completed by late October or early November.
Once the DSMB green-lit the 700mg arm, the trial sites were already activated and waiting. The gates opened. From November through February, enrolling an additional 10 to 15 patients across multiple active sites became standard operating procedure.
4. Big Pharma Demands the 700mg Data
Yes, the core focus is turning the tumor "Hot" via PD-L1 upregulation. But Big Pharma won't write a check based purely on the 350mg dose.
They require Dose-Dependent Correlation. They need to see that 350mg upregulated the biomarker, and 700mg upregulated it even more. If the dose-response splits are missing, the mechanism wouldn't be fully validated. CytoDyn’s clinical team knows exactly what Merck and Roche require to trigger a buyout. They would not waste their AACR debut without showcasing the 700mg mechanism.
The cold-to-hot transition is the undisputed Holy Grail of this trial. But don't let the November PRs anchor your expectations. By the time that poster is pinned to the board in April, the data-lock reflects an ongoing maturing trial (February cut-off) with both doses decently represented, giving the Smart Money the exact forensic proof they need.
This is a breakdown of the AACR submission mechanics which explains the timeline gap between a November PR and an April presentation.
The AACR operates on a tiered timeline. A November PR does not mean the data was frozen in November.
These are the submission mechanics for clinical trials:
The "Regular" Abstract (Mid-November Deadline): This is the baseline submission window. For an ongoing clinical trial, it acts as a "placeholder" submission. It signals to the AACR peer-review committee that the preliminary mechanism (like the first few 350mg patients) are active and the biological trend is valid enough to warrant a spot at the conference.
The "Late-Breaking" & Clinical Trial Abstract (Mid-January Deadline): The AACR specifically reserves a secondary submission window for highly significant, paradigm-shifting clinical data that was not mature enough for the November deadline. If the initial data was profound enough, companies can use this window to present a more comprehensive dataset.
The "Final Data Lock" (Mid-February): This is the crucial piece of the puzzle. For Clinical Trial abstracts, the AACR typically allows researchers to submit a placeholder in January, with the final, updated data cut due in February. This means a trial that submitted an initial abstract in November can continue running patients, clearing DSMB safety hurdles, and dosing the 700mg cohort for an additional three months before the data is officially frozen.
March 17: The AACR publicly posts the abstract titles (and regular abstract texts). This is the embargo-compliant window where the market gets its first glimpse of the vocabulary like "Significant Upregulation".
April 17: The conference begins, the embargo completely lifts, and the full e-posters, containing the mature February data-lock and granular dose-response metrics are published.
When we see the poster in April, the patient population (N) and the dosage splits likely reflect a trial that ran through the winter, not one that stopped in the fall.
However, it's important to look at the actual mechanics of how conferences like the AACR handle these data cutoffs, as well as the speed this trial progressed once the safety hurdles were cleared. If you look at the physics of trial execution, there is in fact a high probability we see the 700mg data, and a patient population (N) much closer to 20 or more.
The data will likely be much more mature than just six or seven patients on 350mg:
1. The November Abstract is a "Placeholder," Not a Tombstone
The data submitted in a November abstract is not the exact same data that is presented on the April poster. That is not how the AACR operates.
Essentially, the November abstract is a "down payment" which secured spot. It proved to the peer-review committee that the biological trend is real.
In fact, the AACR explicitly encourages, and frankly expects, researchers to present the most updated, mature data available at the time the actual poster is printed. Even if the November abstract only referenced the first 5 to 7 patients on 350mg, Dr. Jay and the Creatv Bio team have been continuously feeding new patient data (including the 700mg cohort) into the final April poster.
2. The Late-Breaking & Clinical Trial Window
You noted that if this is a "Clinical Trials" abstract, they can add data as they go. You are 100% correct.
Furthermore, if the initial data was significant enough, the company had the option to utilize the Late-Breaking Abstract deadline, which typically locks in late January or early February. A February data-lock gives them an additional three to four months of clinical runway beyond that mid-November PR, all the way through late February cutoff.
3. The DSMB and the "700mg Floodgate"
You mentioned that the DSMB (Data Safety Monitoring Board) had to look at the 350mg data before authorizing the 700mg dose, which causes a delay.
In oncology, a safety run-in for a new dose usually requires monitoring the first 5 patients for Dose-Limiting Toxicities (DLTs) over a standard 21-to-28 day cycle.
As you know, Leronlimab is not a toxic chemotherapy; it has a remarkably benign safety profile established across thousands of previous patients. The DSMB review for the 350mg cohort was likely a rapid, rubber-stamp process completed by late October or early November.
Once the DSMB green-lit the 700mg arm, the trial sites were already activated and waiting. The gates opened. From November through February, enrolling an additional 10 to 15 patients across multiple active sites became standard operating procedure.
4. Big Pharma Demands the 700mg Data
Yes, the core focus is turning the tumor "Hot" via PD-L1 upregulation. But Big Pharma won't write a check based purely on the 350mg dose.
They require Dose-Dependent Correlation. They need to see that 350mg upregulated the biomarker, and 700mg upregulated it even more. If the dose-response splits are missing, the mechanism wouldn't be fully validated. CytoDyn’s clinical team knows exactly what Merck and Roche require to trigger a buyout. They would not waste their AACR debut without showcasing the 700mg mechanism.
The cold-to-hot transition is the undisputed Holy Grail of this trial. But don't let the November PRs anchor your expectations. By the time that poster is pinned to the board in April, the data-lock reflects an ongoing maturing trial (February cut-off) with both doses decently represented, giving the Smart Money the exact forensic proof they need.
This is a breakdown of the AACR submission mechanics which explains the timeline gap between a November PR and an April presentation.
The AACR operates on a tiered timeline. A November PR does not mean the data was frozen in November.
These are the submission mechanics for clinical trials:
The "Regular" Abstract (Mid-November Deadline): This is the baseline submission window. For an ongoing clinical trial, it acts as a "placeholder" submission. It signals to the AACR peer-review committee that the preliminary mechanism (like the first few 350mg patients) are active and the biological trend is valid enough to warrant a spot at the conference.
The "Late-Breaking" & Clinical Trial Abstract (Mid-January Deadline): The AACR specifically reserves a secondary submission window for highly significant, paradigm-shifting clinical data that was not mature enough for the November deadline. If the initial data was profound enough, companies can use this window to present a more comprehensive dataset.
The "Final Data Lock" (Mid-February): This is the crucial piece of the puzzle. For Clinical Trial abstracts, the AACR typically allows researchers to submit a placeholder in January, with the final, updated data cut due in February. This means a trial that submitted an initial abstract in November can continue running patients, clearing DSMB safety hurdles, and dosing the 700mg cohort for an additional three months before the data is officially frozen.
March 17: The AACR publicly posts the abstract titles (and regular abstract texts). This is the embargo-compliant window where the market gets its first glimpse of the vocabulary like "Significant Upregulation".
April 17: The conference begins, the embargo completely lifts, and the full e-posters, containing the mature February data-lock and granular dose-response metrics are published.
When we see the poster in April, the patient population (N) and the dosage splits likely reflect a trial that ran through the winter, not one that stopped in the fall.
16
1
